Cartesian Therapeutics (RNAC) Tops Q2 EPS by 134c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.46, $1.34 better than the analyst estimate of ($0.88).
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Street Research Upgrades Intel (INTC) to Buy
- NASA JPL taps Karman Space for Mars SkyFall parachute system
- Sierra Bancorp (BSRR) Tops Q3 EPS by 27c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
